The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan
Background There is no consensus on the appropriate surveillance for high-risk women with breast cancer in Japan. We investigated their imaging features and pathological characteristics to build a proper surveillance system for asymptomatic high-risk individuals in the future. Methods We retrospecti...
Gespeichert in:
| Veröffentlicht in: | Breast cancer (Tokyo, Japan) Japan), 2019-09, Vol.26 (5), p.552-561 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 561 |
|---|---|
| container_issue | 5 |
| container_start_page | 552 |
| container_title | Breast cancer (Tokyo, Japan) |
| container_volume | 26 |
| creator | Murakami, Wakana Tozaki, Mitsuhiro Nakamura, Seigo Ide, Yoshimi Inuzuka, Mayuko Hirota, Yuko Murakami, Kouzou Takahama, Noritsugu Ohgiya, Yoshimitsu Gokan, Takehiko |
| description | Background
There is no consensus on the appropriate surveillance for high-risk women with breast cancer in Japan. We investigated their imaging features and pathological characteristics to build a proper surveillance system for asymptomatic high-risk individuals in the future.
Methods
We retrospectively reviewed 93 female (median age 43 years) BRCA1 and BRCA2 mutation carriers from our institutional clinical database from 2011 to 2017. The study population was composed of 112 breast cancers. Mammography and MRI were reviewed by examiners blinded to patients’ clinical history. Final surgical or biopsy histopathology served as the reference standard in all the patients.
Results
Fifty-nine breast cancers met selection criteria; of these, 30 were BRCA1-associated tumors, and 29 were BRCA2-associated tumors. Invasive ductal carcinoma was the most prevalent type in both BRCA1 and BRCA2. There were statistically significant differences in phenotype, nuclear grade, and Ki-67 labeling index between BRCA1 and BRCA2 mutation carriers. Additionally, imaging findings on mammography and MRI were statistically different. Tumors in BRCA2 carriers demonstrated mammographic calcifications more frequently, while those in BRCA1 carriers demonstrated a mass or architectural distortion (
P
|
| doi_str_mv | 10.1007/s12282-019-00955-6 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6694035</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A712280546</galeid><sourcerecordid>A712280546</sourcerecordid><originalsourceid>FETCH-LOGICAL-c603t-2ba4f48df9565e63ad3e489fddb9814cac4172e335ae9e18f1f3a76f2d3e25be3</originalsourceid><addsrcrecordid>eNp9kU2LFDEQhoMo7rr6BzxIwHOvlY9Opz0I4-DHyoqwrBcvIZOuzGbpTpqkR_Dfm7F1cUEkhwqp531J1UvIcwbnDKB7VRjnmjfA-gagb9tGPSCnTGtoJBfiYb0LCY3SSp-QJ6XcAkjRgXpMTgRoDj2Xp-Tb9Q1SN4YYnB1pmGbrFpo8_Xx1QYvLiDHEPfUp07dX2w2dDotdQorU2ZwD5vKaLtXAh1wWmnFOeaEh0k92tvEpeeTtWPDZ73pGvr5_d7392Fx--XCx3Vw2ToFYGr6z0ks9-L5VLSphB4FS934Ydr1m0lknWcdRiNZij0x75oXtlOeV4-0OxRl5s_rOh92Eg8O4ZDuaOYfJ5h8m2WDud2K4Mfv03SjVSxBtNXi5GuztiCZEnyrmplCc2XTHHUMrVaXO_0HVM-AUXIroQ32_J-CrwOVUSkZ_9yUG5higWQM0NUDzK0BzFL34e5g7yZ_EKiBWoNRW3GM2t-mQY13w_2x_Ah4Xpmg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan</title><source>MEDLINE</source><source>SpringerLink</source><creator>Murakami, Wakana ; Tozaki, Mitsuhiro ; Nakamura, Seigo ; Ide, Yoshimi ; Inuzuka, Mayuko ; Hirota, Yuko ; Murakami, Kouzou ; Takahama, Noritsugu ; Ohgiya, Yoshimitsu ; Gokan, Takehiko</creator><creatorcontrib>Murakami, Wakana ; Tozaki, Mitsuhiro ; Nakamura, Seigo ; Ide, Yoshimi ; Inuzuka, Mayuko ; Hirota, Yuko ; Murakami, Kouzou ; Takahama, Noritsugu ; Ohgiya, Yoshimitsu ; Gokan, Takehiko</creatorcontrib><description>Background
There is no consensus on the appropriate surveillance for high-risk women with breast cancer in Japan. We investigated their imaging features and pathological characteristics to build a proper surveillance system for asymptomatic high-risk individuals in the future.
Methods
We retrospectively reviewed 93 female (median age 43 years) BRCA1 and BRCA2 mutation carriers from our institutional clinical database from 2011 to 2017. The study population was composed of 112 breast cancers. Mammography and MRI were reviewed by examiners blinded to patients’ clinical history. Final surgical or biopsy histopathology served as the reference standard in all the patients.
Results
Fifty-nine breast cancers met selection criteria; of these, 30 were BRCA1-associated tumors, and 29 were BRCA2-associated tumors. Invasive ductal carcinoma was the most prevalent type in both BRCA1 and BRCA2. There were statistically significant differences in phenotype, nuclear grade, and Ki-67 labeling index between BRCA1 and BRCA2 mutation carriers. Additionally, imaging findings on mammography and MRI were statistically different. Tumors in BRCA2 carriers demonstrated mammographic calcifications more frequently, while those in BRCA1 carriers demonstrated a mass or architectural distortion (
P
< 0.001). Enhancement pattern on MRI also significantly differed between the two subgroups (
P
= 0.006). The size of MRI-detected lesions was statistically smaller than the size of those detected by other modalities (
P
= 0.004).
Conclusions
The imaging and histological characteristics of BRCA1/2 mutation carriers were consistent with other countries’ studies. MRI-detected lesions were significantly smaller than lesions detected by non-MRI modality. All lesions in BRCA1 mutation carriers could be detected by MRI.</description><identifier>ISSN: 1340-6868</identifier><identifier>EISSN: 1880-4233</identifier><identifier>DOI: 10.1007/s12282-019-00955-6</identifier><identifier>PMID: 30820924</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Adult ; Aged ; Biopsy ; Breast Neoplasms - diagnostic imaging ; Breast Neoplasms - genetics ; Breast Neoplasms - pathology ; Cancer ; Cancer Research ; Carcinoma, Ductal, Breast - diagnostic imaging ; Carcinoma, Ductal, Breast - genetics ; Carcinoma, Ductal, Breast - pathology ; Female ; Follow-Up Studies ; Gadobutrol ; Gene mutations ; Genes, BRCA1 ; Genes, BRCA2 ; Genetic aspects ; Health aspects ; Humans ; Japan ; Magnetic Resonance Imaging ; Mammography ; Mass Screening - methods ; Medical colleges ; Medicine ; Medicine & Public Health ; Middle Aged ; Mutation ; Oncology ; Oncology, Experimental ; Original ; Original Article ; Public Health Surveillance - methods ; Retrospective Studies ; Surgery ; Surgical Oncology ; Young Adult</subject><ispartof>Breast cancer (Tokyo, Japan), 2019-09, Vol.26 (5), p.552-561</ispartof><rights>The Author(s) 2019</rights><rights>COPYRIGHT 2019 Springer</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c603t-2ba4f48df9565e63ad3e489fddb9814cac4172e335ae9e18f1f3a76f2d3e25be3</citedby><cites>FETCH-LOGICAL-c603t-2ba4f48df9565e63ad3e489fddb9814cac4172e335ae9e18f1f3a76f2d3e25be3</cites><orcidid>0000-0002-7956-6052</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12282-019-00955-6$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12282-019-00955-6$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,315,781,785,886,27929,27930,41493,42562,51324</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30820924$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Murakami, Wakana</creatorcontrib><creatorcontrib>Tozaki, Mitsuhiro</creatorcontrib><creatorcontrib>Nakamura, Seigo</creatorcontrib><creatorcontrib>Ide, Yoshimi</creatorcontrib><creatorcontrib>Inuzuka, Mayuko</creatorcontrib><creatorcontrib>Hirota, Yuko</creatorcontrib><creatorcontrib>Murakami, Kouzou</creatorcontrib><creatorcontrib>Takahama, Noritsugu</creatorcontrib><creatorcontrib>Ohgiya, Yoshimitsu</creatorcontrib><creatorcontrib>Gokan, Takehiko</creatorcontrib><title>The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan</title><title>Breast cancer (Tokyo, Japan)</title><addtitle>Breast Cancer</addtitle><addtitle>Breast Cancer</addtitle><description>Background
There is no consensus on the appropriate surveillance for high-risk women with breast cancer in Japan. We investigated their imaging features and pathological characteristics to build a proper surveillance system for asymptomatic high-risk individuals in the future.
Methods
We retrospectively reviewed 93 female (median age 43 years) BRCA1 and BRCA2 mutation carriers from our institutional clinical database from 2011 to 2017. The study population was composed of 112 breast cancers. Mammography and MRI were reviewed by examiners blinded to patients’ clinical history. Final surgical or biopsy histopathology served as the reference standard in all the patients.
Results
Fifty-nine breast cancers met selection criteria; of these, 30 were BRCA1-associated tumors, and 29 were BRCA2-associated tumors. Invasive ductal carcinoma was the most prevalent type in both BRCA1 and BRCA2. There were statistically significant differences in phenotype, nuclear grade, and Ki-67 labeling index between BRCA1 and BRCA2 mutation carriers. Additionally, imaging findings on mammography and MRI were statistically different. Tumors in BRCA2 carriers demonstrated mammographic calcifications more frequently, while those in BRCA1 carriers demonstrated a mass or architectural distortion (
P
< 0.001). Enhancement pattern on MRI also significantly differed between the two subgroups (
P
= 0.006). The size of MRI-detected lesions was statistically smaller than the size of those detected by other modalities (
P
= 0.004).
Conclusions
The imaging and histological characteristics of BRCA1/2 mutation carriers were consistent with other countries’ studies. MRI-detected lesions were significantly smaller than lesions detected by non-MRI modality. All lesions in BRCA1 mutation carriers could be detected by MRI.</description><subject>Adult</subject><subject>Aged</subject><subject>Biopsy</subject><subject>Breast Neoplasms - diagnostic imaging</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Carcinoma, Ductal, Breast - diagnostic imaging</subject><subject>Carcinoma, Ductal, Breast - genetics</subject><subject>Carcinoma, Ductal, Breast - pathology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gadobutrol</subject><subject>Gene mutations</subject><subject>Genes, BRCA1</subject><subject>Genes, BRCA2</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Japan</subject><subject>Magnetic Resonance Imaging</subject><subject>Mammography</subject><subject>Mass Screening - methods</subject><subject>Medical colleges</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Oncology, Experimental</subject><subject>Original</subject><subject>Original Article</subject><subject>Public Health Surveillance - methods</subject><subject>Retrospective Studies</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Young Adult</subject><issn>1340-6868</issn><issn>1880-4233</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kU2LFDEQhoMo7rr6BzxIwHOvlY9Opz0I4-DHyoqwrBcvIZOuzGbpTpqkR_Dfm7F1cUEkhwqp531J1UvIcwbnDKB7VRjnmjfA-gagb9tGPSCnTGtoJBfiYb0LCY3SSp-QJ6XcAkjRgXpMTgRoDj2Xp-Tb9Q1SN4YYnB1pmGbrFpo8_Xx1QYvLiDHEPfUp07dX2w2dDotdQorU2ZwD5vKaLtXAh1wWmnFOeaEh0k92tvEpeeTtWPDZ73pGvr5_d7392Fx--XCx3Vw2ToFYGr6z0ks9-L5VLSphB4FS934Ydr1m0lknWcdRiNZij0x75oXtlOeV4-0OxRl5s_rOh92Eg8O4ZDuaOYfJ5h8m2WDud2K4Mfv03SjVSxBtNXi5GuztiCZEnyrmplCc2XTHHUMrVaXO_0HVM-AUXIroQ32_J-CrwOVUSkZ_9yUG5higWQM0NUDzK0BzFL34e5g7yZ_EKiBWoNRW3GM2t-mQY13w_2x_Ah4Xpmg</recordid><startdate>20190901</startdate><enddate>20190901</enddate><creator>Murakami, Wakana</creator><creator>Tozaki, Mitsuhiro</creator><creator>Nakamura, Seigo</creator><creator>Ide, Yoshimi</creator><creator>Inuzuka, Mayuko</creator><creator>Hirota, Yuko</creator><creator>Murakami, Kouzou</creator><creator>Takahama, Noritsugu</creator><creator>Ohgiya, Yoshimitsu</creator><creator>Gokan, Takehiko</creator><general>Springer Japan</general><general>Springer</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7956-6052</orcidid></search><sort><creationdate>20190901</creationdate><title>The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan</title><author>Murakami, Wakana ; Tozaki, Mitsuhiro ; Nakamura, Seigo ; Ide, Yoshimi ; Inuzuka, Mayuko ; Hirota, Yuko ; Murakami, Kouzou ; Takahama, Noritsugu ; Ohgiya, Yoshimitsu ; Gokan, Takehiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c603t-2ba4f48df9565e63ad3e489fddb9814cac4172e335ae9e18f1f3a76f2d3e25be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biopsy</topic><topic>Breast Neoplasms - diagnostic imaging</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Carcinoma, Ductal, Breast - diagnostic imaging</topic><topic>Carcinoma, Ductal, Breast - genetics</topic><topic>Carcinoma, Ductal, Breast - pathology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gadobutrol</topic><topic>Gene mutations</topic><topic>Genes, BRCA1</topic><topic>Genes, BRCA2</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Japan</topic><topic>Magnetic Resonance Imaging</topic><topic>Mammography</topic><topic>Mass Screening - methods</topic><topic>Medical colleges</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Oncology, Experimental</topic><topic>Original</topic><topic>Original Article</topic><topic>Public Health Surveillance - methods</topic><topic>Retrospective Studies</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Murakami, Wakana</creatorcontrib><creatorcontrib>Tozaki, Mitsuhiro</creatorcontrib><creatorcontrib>Nakamura, Seigo</creatorcontrib><creatorcontrib>Ide, Yoshimi</creatorcontrib><creatorcontrib>Inuzuka, Mayuko</creatorcontrib><creatorcontrib>Hirota, Yuko</creatorcontrib><creatorcontrib>Murakami, Kouzou</creatorcontrib><creatorcontrib>Takahama, Noritsugu</creatorcontrib><creatorcontrib>Ohgiya, Yoshimitsu</creatorcontrib><creatorcontrib>Gokan, Takehiko</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Breast cancer (Tokyo, Japan)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Murakami, Wakana</au><au>Tozaki, Mitsuhiro</au><au>Nakamura, Seigo</au><au>Ide, Yoshimi</au><au>Inuzuka, Mayuko</au><au>Hirota, Yuko</au><au>Murakami, Kouzou</au><au>Takahama, Noritsugu</au><au>Ohgiya, Yoshimitsu</au><au>Gokan, Takehiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan</atitle><jtitle>Breast cancer (Tokyo, Japan)</jtitle><stitle>Breast Cancer</stitle><addtitle>Breast Cancer</addtitle><date>2019-09-01</date><risdate>2019</risdate><volume>26</volume><issue>5</issue><spage>552</spage><epage>561</epage><pages>552-561</pages><issn>1340-6868</issn><eissn>1880-4233</eissn><abstract>Background
There is no consensus on the appropriate surveillance for high-risk women with breast cancer in Japan. We investigated their imaging features and pathological characteristics to build a proper surveillance system for asymptomatic high-risk individuals in the future.
Methods
We retrospectively reviewed 93 female (median age 43 years) BRCA1 and BRCA2 mutation carriers from our institutional clinical database from 2011 to 2017. The study population was composed of 112 breast cancers. Mammography and MRI were reviewed by examiners blinded to patients’ clinical history. Final surgical or biopsy histopathology served as the reference standard in all the patients.
Results
Fifty-nine breast cancers met selection criteria; of these, 30 were BRCA1-associated tumors, and 29 were BRCA2-associated tumors. Invasive ductal carcinoma was the most prevalent type in both BRCA1 and BRCA2. There were statistically significant differences in phenotype, nuclear grade, and Ki-67 labeling index between BRCA1 and BRCA2 mutation carriers. Additionally, imaging findings on mammography and MRI were statistically different. Tumors in BRCA2 carriers demonstrated mammographic calcifications more frequently, while those in BRCA1 carriers demonstrated a mass or architectural distortion (
P
< 0.001). Enhancement pattern on MRI also significantly differed between the two subgroups (
P
= 0.006). The size of MRI-detected lesions was statistically smaller than the size of those detected by other modalities (
P
= 0.004).
Conclusions
The imaging and histological characteristics of BRCA1/2 mutation carriers were consistent with other countries’ studies. MRI-detected lesions were significantly smaller than lesions detected by non-MRI modality. All lesions in BRCA1 mutation carriers could be detected by MRI.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>30820924</pmid><doi>10.1007/s12282-019-00955-6</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-7956-6052</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1340-6868 |
| ispartof | Breast cancer (Tokyo, Japan), 2019-09, Vol.26 (5), p.552-561 |
| issn | 1340-6868 1880-4233 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6694035 |
| source | MEDLINE; SpringerLink |
| subjects | Adult Aged Biopsy Breast Neoplasms - diagnostic imaging Breast Neoplasms - genetics Breast Neoplasms - pathology Cancer Cancer Research Carcinoma, Ductal, Breast - diagnostic imaging Carcinoma, Ductal, Breast - genetics Carcinoma, Ductal, Breast - pathology Female Follow-Up Studies Gadobutrol Gene mutations Genes, BRCA1 Genes, BRCA2 Genetic aspects Health aspects Humans Japan Magnetic Resonance Imaging Mammography Mass Screening - methods Medical colleges Medicine Medicine & Public Health Middle Aged Mutation Oncology Oncology, Experimental Original Original Article Public Health Surveillance - methods Retrospective Studies Surgery Surgical Oncology Young Adult |
| title | The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T19%3A28%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20clinical%20impact%20of%20MRI%20screening%20for%20BRCA%20mutation%20carriers:%20the%20first%20report%20in%20Japan&rft.jtitle=Breast%20cancer%20(Tokyo,%20Japan)&rft.au=Murakami,%20Wakana&rft.date=2019-09-01&rft.volume=26&rft.issue=5&rft.spage=552&rft.epage=561&rft.pages=552-561&rft.issn=1340-6868&rft.eissn=1880-4233&rft_id=info:doi/10.1007/s12282-019-00955-6&rft_dat=%3Cgale_pubme%3EA712280546%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/30820924&rft_galeid=A712280546&rfr_iscdi=true |